argenx SE

( )
ARGX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
CTLTCatalent, Inc. 2.59%84.102.1%$245.35m
SAVACassava Sciences, Inc. -2.70%11.160.0%$215.29m
HZNPHorizon Therapeutics Plc 1.82%79.675.8%$175.38m
JAZZJazz Pharmaceuticals Plc 1.37%141.492.4%$172.13m
MRNSMarinus Pharmaceuticals, Inc. 0.99%11.267.8%$129.52m
CORTCorcept Therapeutics, Inc. 1.46%17.345.5%$128.22m
VRXValeant Pharmaceuticals International, Inc. -0.13%15.2814.1%$89.91m
MYOKMyoKardia, Inc. 0.89%133.901.8%$63.32m
BHCBausch Health Cos., Inc. -0.13%15.280.0%$62.17m
AMRNAmarin Corp. Plc 4.99%4.001.5%$59.91m
ARGXargenx SE 2.74%255.370.0%$55.91m
SAGESAGE Therapeutics, Inc. -1.53%59.898.6%$45.78m
GWPHGW Pharmaceuticals Plc -0.94%99.506.2%$40.15m
AXSMAxsome Therapeutics, Inc. -0.73%76.461.9%$40.04m
PRGOPerrigo Co. Plc 0.80%45.606.8%$37.20m

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.